Rigel Pharmaceuticals (RIGL) Competitors $34.72 -0.39 (-1.11%) Closing price 04:00 PM EasternExtended Trading$35.20 +0.48 (+1.38%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RIGL vs. FOLD, MNKD, BCRX, CLDX, NVAX, INVA, OPK, DVAX, ZBIO, and GERNShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Amicus Therapeutics (FOLD), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), and Geron (GERN). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Its Competitors Amicus Therapeutics MannKind BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva OPKO Health Dynavax Technologies Zenas BioPharma Geron Rigel Pharmaceuticals (NASDAQ:RIGL) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Does the media refer more to RIGL or FOLD? In the previous week, Amicus Therapeutics had 4 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 11 mentions for Amicus Therapeutics and 7 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.02 beat Amicus Therapeutics' score of 0.97 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RIGL or FOLD? Rigel Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Which has higher earnings and valuation, RIGL or FOLD? Rigel Pharmaceuticals has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$179.28M3.47$17.49M$5.416.42Amicus Therapeutics$528.29M4.86-$56.11M-$0.12-69.42 Do institutionals & insiders believe in RIGL or FOLD? 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 9.5% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer RIGL or FOLD? Rigel Pharmaceuticals currently has a consensus price target of $38.20, indicating a potential upside of 10.02%. Amicus Therapeutics has a consensus price target of $15.78, indicating a potential upside of 89.41%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Amicus Therapeutics is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Amicus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Is RIGL or FOLD more profitable? Rigel Pharmaceuticals has a net margin of 36.51% compared to Amicus Therapeutics' net margin of -6.67%. Rigel Pharmaceuticals' return on equity of 438.89% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals36.51% 438.89% 57.03% Amicus Therapeutics -6.67%-5.07%-1.23% SummaryRigel Pharmaceuticals beats Amicus Therapeutics on 10 of the 16 factors compared between the two stocks. Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$629.78M$2.58B$5.79B$10.40BDividend YieldN/A55.37%5.63%4.60%P/E Ratio6.4222.7276.4826.75Price / Sales3.47689.96531.95124.23Price / Cash32.54175.2537.9261.55Price / Book182.745.3513.726.40Net Income$17.49M$32.95M$3.29B$271.62M7 Day Performance-8.54%0.90%1.03%2.85%1 Month Performance-10.84%6.78%6.32%9.64%1 Year Performance153.62%-3.47%81.16%31.62% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals2.4913 of 5 stars$34.72-1.1%$38.20+10.0%+157.6%$629.78M$179.28M6.42160News CoveragePositive NewsFOLDAmicus Therapeutics4.0653 of 5 stars$7.73-3.3%$16.00+107.0%-22.3%$2.46B$528.29M-64.41480Analyst UpgradeMNKDMannKind4.2889 of 5 stars$5.38-3.4%$11.17+107.6%-15.8%$1.71B$285.50M48.91400Positive NewsAnalyst ForecastInsider TradeShort Interest ↓BCRXBioCryst Pharmaceuticals4.2782 of 5 stars$7.70-2.7%$16.70+116.9%+0.0%$1.66B$450.71M-42.78530Positive NewsCLDXCelldex Therapeutics2.1912 of 5 stars$24.50+0.2%$46.67+90.5%-38.1%$1.62B$7.02M-8.14150Analyst ForecastNVAXNovavax4.213 of 5 stars$8.08+1.3%$14.29+76.8%-32.1%$1.30B$682.16M3.541,990INVAInnoviva4.8422 of 5 stars$19.55+0.9%$42.75+118.7%+1.8%$1.22B$358.71M63.07100Positive NewsShort Interest ↓OPKOPKO Health4.3492 of 5 stars$1.38-1.4%$2.75+99.3%-6.8%$1.11B$713.10M-5.522,997DVAXDynavax Technologies4.3136 of 5 stars$9.36-0.5%$24.33+160.0%-13.0%$1.10B$277.25M-20.35350Positive NewsZBIOZenas BioPharma1.095 of 5 stars$21.95+8.5%$36.67+67.0%N/A$851.89M$5M0.00N/AGERNGeron3.0181 of 5 stars$1.27flat$3.79+198.1%-70.8%$810.28M$76.99M-9.7770 Related Companies and Tools Related Companies Amicus Therapeutics Alternatives MannKind Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Zenas BioPharma Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RIGL) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RIGL Stock Alerts